About Anco Biotech Group

Anco Biotech Group is a multinational corporation specializing in the global commercialization of biotechnology healthcare products, headquartered in Hong Kong. The Group is a professional promoter of innovative medical products, committed to translating cutting-edge biotechnology into medical products and solutions. We are expanding our global distribution network across key markets including Hong Kong, Asian countries, and EU countries, delivering innovative biotech medical products and solutions to government medical institutions, health examination centers, insurance companies, corporate groups, and home users.

Currently, the Group is focused on expanding the global distribution network for its first authorized product - the Test-Reagent for 5-hydroxyindoleacetic acid (Qualitative Colorimetric Method) (used in early screening of multiple cancers*), and commercializing the product in global markets. With core strengths in professional distribution networks, compliant warehousing and logistics, and localized technical support, we drive the development of global healthcare.

  • Note: Test results must be comprehensively evaluated alongside clinical examinations and should not be used as a basis for cancer diagnosis. For details regarding the product's sensitivity in detecting certain tumors and cancers, please refer to Section 1 of the "Special Attention and Disclaimer" on this website.

Manufacturer Introduction

Wuhan Chenkang Technology Co., Ltd. (“Chenkang”) is a high-tech enterprise specializing in cancer preventive medicine and the healthcare industry. Chenkang headquartered in the East Lake National Economic Development Zone in Wuhan, China, the company is dedicated to the innovative R&D of early cancer screening and intervention technologies.

A series of high-tech products including the "Test-Reagent for 5-hydroxyindoleacetic acid (Qualitative Colorimetric Method)", widely used in the field of early cancer screening.

Core Strengths of Manufacturer

Deep expertise in preventive medicine, focusing on early cancer screening and intervention technologies;
Supported by leading research institutions such as Wuhan University, with an R&D team led by senior experts. Clinical research data has been published in multiple authoritative medical journals, demonstrating technical reliability and industry recognition;
Specializes in the innovative development of medical devices and functional foods, holding multiple national invention patents; and
The manufacturing and products are certified to GMP (China NMPA), U.S. FDA, EU CE, and ISO 13485 international standards.

Authoritative Collaborations of Manufacturer

Chenkang collaborates extensively with leading medical institutions across China to jointly advance the clinical validation and application of cancer prevention technologies. Key partners include, but are not limited to:

Cancer Hospital Chinese Academy of Medical Sciences
Peking University Cancer Hospital
The First Affiliated Hospital of Sun Yat-sen University
Hubei Cancer Hospital
Zhongnan Hospital of Wuhan University
Wuhan Central Hospital
Wuhan Iron and Steel General Hospital
Hubei Maternal and Child Health Hospital
Zhanjiang 422 Hospital of the PLA
Shenzhen Hong Kong Garrison Hospital
Yunnan Yunze County People's Hospital
Jiangmen People's Hospital of Guangdong Province

Partners

Manufacturer

Wuhan Chenkang Technology Company Limited

Room 02, Floor 3, Unit 2, Building 23, Wuhan Optical Valley International Biomedical Accelerator, Phase 1.2, the 2nd High-Tech Road 388, East Lake New Technology Development Zone, Wuhan City, China

Hong Kong Sub-Agent

PMT Group Limited

Suite 1106-08, 11/F, Tai Yau Building, No. 181 Johnston Road, Wanchai, Hong Kong